Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT®) in attention-deficit hyperactivity disorder: a profile of their use
- 65 Downloads
Amphetamine extended-release oral suspension (Adzenys ER™) and extended-release orally disintegrating tablets (Adzenys XR-ODT®) are easy-to-administer, long-acting, and convenient CNS stimulant options for treating attention-deficit hyperactivity disorder (ADHD) in children aged ≥ 6 years, adolescents, and adults. The bioavailability of d- and l-amphetamine with Adzenys ER™ suspension and XR-ODT® is equivalent to that of a corresponding dose of the reference product [i.e. mixed amphetamine salt extended-release capsules (MAS ER)], which has well-established efficacy, tolerability, and safety profiles. As Adzenys ER™ suspension/XR-ODT® contain both immediate- and extended-release amphetamine particles, plasma concentrations of d- and l-amphetamine increase rapidly, remain relatively stable for several hours, then slowly decline, allowing for once-daily administration. The use of Adzenys ER™ suspension/XR-ODT® may be of particular benefit in individuals who require a rapid onset and prolonged reduction in ADHD symptoms, as well as those who have difficulty swallowing tablets or capsules whole (neither formulation requires swallowing whole tablets/capsules, and both may be taken without regard to food).
The manuscript was reviewed by: A.C. Childress, Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA; R.H. Howland, University of Pittsburgh School of Medicine, and Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA; A.S. Poulton, Sydney Medical School Nepean, The University of Sydney, and Department of Paediatrics, Nepean Hospital, Penrith, NSW, Australia; B.J. Warren, College of Nursing, The Ohio State University, Columbus, OH, USA. During the peer review process, the manufacturer of Adzenys ER™/XR-ODT® was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.
The preparation of this review was not supported by any external funding.
Compliance with ethical standards
Conflict of interest
K.A. Lyseng-Williamson is an employee of Adis/Springer, is responsible for the article content and declares no conflicts of interest.
- 1.Subcommittee on Attention-Deficit/Hyperactivity Disorder; Steering Committee on Quality Improvement and Management, Wolraich M, Brown L, Brown RT, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–22.CrossRefPubMedCentralGoogle Scholar
- 2.Danielson ML, Visser SN, Chronis-Tuscano A, et al. A national description of treatment among United States children and adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2018;192(240–246):e1.Google Scholar
- 5.National Collaborating Centre for Mental Health (UK). Attention deficit hyperactivity disorder: diagnosis and management of ADHD in children, young people and adults. NICE guideline no. 87. Leicester (UK): British Psychological Society; 2018.Google Scholar
- 9.Adzenys ER (amphetamine) extended-release oral suspension: US prescribing Information. Grand Prairie (TX): Neos Therapeutics, Inc.; 2017.Google Scholar
- 10.Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, CII: US prescribing Information. Grand Prairie (TX): Neos Therapeutics, Inc.; 2017.Google Scholar
- 12.Sikes C, Stark JG, McMahen R, et al. A single-dose, two-way crossover, open-label bioequivalence study of an amphetamine extended-release oral suspension in healthy adults. J Atten Disord. 2017:1087054717743329. https://doi.org/10.1177/1087054717743329.
- 16.Spencer TJ, Wilens TE, Biederman J, et al. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther. 2006;28(2):266–79.CrossRefPubMedGoogle Scholar